We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tolerance and complications of therapeutic plasma exchange by centrifugation: A single center experience.
- Authors
Coirier, Valentin; Lesouhaitier, Mathieu; Reizine, Florian; Painvin, Benoît; Quelven, Quentin; Maamar, Adel; Gacouin, Arnaud; Tadié, Jean‐Marc; Le Tulzo, Yves; Camus, Christophe
- Abstract
Introduction: Therapeutic plasma exchange (TPE) constitutes an important therapy for hematological, neurological, immunological, and nephrological diseases. Most studies have focused on efficacy, whereas tolerance and complications during sessions have been less well studied and not recently. Material and methods: We conducted a single center retrospective study of all patients who underwent TPE between 2011 and 2018. TPE sessions using the centrifugation technique were performed by dedicated trained nurses. Specific side effects were identified through surveillance forms completed contemporaneously. The primary outcome was the rate of all‐type adverse effects that occurred during the TPE sessions. Results: In total, 1895 TPE sessions performed on 185 patients were analyzed. At least one adverse effect was reported for 805 sessions (42.5% [29.9%‐70.1%]), corresponding to 171 patients (92.4% [87.6%‐95.8%]). Hypotension occurred during 288 sessions (15.2%), was asymptomatic in 95.8% of cases, and more frequent with the use of 4% albumin than fresh frozen plasma (FFP) (19.8 vs 8.9%, P <.0001). Hypocalcemia occurred during 370 sessions (19.6%) and was more frequent with the use of FFP than with the use of albumin alone (FFP alone: 28.0%, albumin + FFP: 26%, albumin alone: 11.7%; P <.0001). Allergic reactions occurred during 56 sessions (3%), exclusively with FFP. Severe adverse effects were reported for 0.3% of sessions and 5.4% of patients. Conclusions: TPE is a safe therapy when performed by a trained team. Adverse effects were frequent but mostly not serious. The replacement fluid was the main determinant of the occurrence of complications. (ClinicalTrials.gov ID: NCT03888417).
- Subjects
PLASMA exchange (Therapeutics); CENTRIFUGATION; THERAPEUTIC complications; PLASMA products; ALLERGIES
- Publication
Journal of Clinical Apheresis, 2022, Vol 37, Issue 1, p54
- ISSN
0733-2459
- Publication type
Article
- DOI
10.1002/jca.21950